Alteration in p53 modulates glial proteins in human glial tumour cells.
In transformed human glial cells, abnormalities of the p53 gene and altered expression of glial-specific properties (GSPs) have been observed. We therefore investigated whether (i) expression of the altered p53 protein is involved in the reduced expression of GSPs; and (ii) expression of the wild-type p53 (wt-p53) gene leads to induction of GSPs. We first determined that the p53 gene is mutated in human glioblastoma U-373MG cells. In these cells, and in human T-98G glioblastoma cells reported to possess a mutated p53 (m-p53) gene, nuclear m-p53 expression was intense while GSP expression was low in the same cell as revealed by double labelling immunocytochemistry. Conversely, glial fibrillary acidic protein (GFAP) and glutamate synthase (GS) were expressed in cells devoid of nuclear m-p53 immnunoreactivity. Therefore, a mutually exclusive relationship exists between the cytoplasmic GSPs and nuclear m-p53. Upon treatment with retinoic acid (RA) and dibutyryl cyclic AMP (dbcAMP), overall GSP staining were increased concomitant with suppression of nuclear m-p53. Their mutually exclusive expression pattern was maintained suggesting a functional relationship. This is supported by the observation of a similar mutually exclusive expression pattern for p53 and GSPs in pathologic specimens of human glioblastoma tissues. We then explored the role of the wt-p53 gene in the induction of GSPs using a wt-p53 tetracycline-regulated conditional expression system in human LN-Z308 glioblastoma cells. These cells normally express no p53 and no appreciable levels of GS or GFAP. Induced expression of wt-p53 lead to induction of GSP. These observations are consistent with the hypotheses that (i) nuclear m-p53 expression and cytoplasmic expression of GFAP and GS are inversely correlated, and (ii) expression of the wt-p53 gene leads to the expression of GSPs.
U
H S
HS
Division of Neurological Surgery, School of Medicine, University of California, San Diego, USA. hoisang@ucsd.edu
Banaie
A
A
Rigby
L
L
Chen
J
J
Meltzer
H
H
D000595:Amino Acid Sequence; D001483:Base Sequence; D001932:Brain Neoplasms; D003994:Bucladesine / Q000494:pharmacology; D017124:Conserved Sequence; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D016158:Genes, p53; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis / Q000235:genetics*; D005909:Glioblastoma; D005974:Glutamate-Ammonia Ligase / Q000032:analysis / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D016297:Mutagenesis, Site-Directed; D010751:Phosphopyruvate Hydratase / Q000032:analysis / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics*
D005904:Glial Fibrillary Acidic Protein; D016159:Tumor Suppressor Protein p53; D014212:Tretinoin; D003994:Bucladesine; D010751:Phosphopyruvate Hydratase; D005974:Glutamate-Ammonia Ligase